Clinical trials are research studies that are designed to determine whether a potential medicine is safe and effective for patients. Patients may participate in ongoing clinical trials of Xencor’s investigational drug candidates if they meet certain enrollment criteria.
Conditions: Healthy Participants, Ulcerative Colitis (UC)
Phase: Phase 1/2
Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Phase: Phase 1
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.
Conditions: Clear Cell Renal Cell Carcinoma
Phase: Phase 1
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Castration-resistant Prostate Cancer, Epithelial Ovarian Cancer, TNBC – Triple-Negative Breast Cancer, Colorectal Cancer
Phase: Phase 1
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Information about Xencor’s clinical trials is available at www.clinicaltrials.gov.